ASCO has called for raising awareness to control obesity, as it is not just a risk factor for developing diabetes but also for cancer.
Journal of Clinical Oncology
ASCO called for increased education, research and advocacy to reduce the toll of obesity, both as a leading cause of cancer and a complication in the care of cancer patients. ASCO recommendations outline four critical priorities, including increased education and awareness about links between obesity and cancer; development of new physician tools and resources; intensified and highly coordinated research; and policy changes to increase access to obesity screening, diagnosis and treatment. The statement was published online on October 1, 2014 in the .
In releasing its first-ever policy statement on cancer and obesity, ASCO underscores that obesity is becoming a central challenge in cancer prevention and care, and is projected to soon overtake tobacco as the leading preventable cause of cancer in the United States. By 2030, almost a half million Americans may be diagnosed with obesity-related cancers annually.Among people with cancer, obesity can increase the risk of cancer recurrence and lower survival. In fact, one study suggests that being overweight or obese contributes to as many as one in five cancer-related deaths.
Link to the ASCO press release: http://bit.ly/1nKB7HT
Article in Evidence-Based Oncology on the obesity-cancer link: http://bit.ly/UfMV7t
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Exploring Pharmaceutical Innovations, Trust, and Access With CVS Health's CMO
July 11th 2024On this episode of Managed Care Cast, we're talking with the chief medical officer of CVS Health about recent pharmaceutical innovations, patient-provider relationships, and strategies to reduce drug costs.
Listen
FDA Approves Danziten for Chronic Myeloid Leukemia Without Mealtime Restrictions
November 14th 2024The FDA has granted approval to Azurity Pharmaceuticals' nilotinib tablets (Danziten), a novel version of the tyrosine kinase inhibitor for chronic myeloid leukemia that can be taken without mealtime restrictions.
Read More